Estimating the risk for secondary cancer following targeted alpha therapy with astatine-211 intraperitoneal radioimmunotherapy.

MLA

Leidermark, Erik, et al. “Estimating the Risk for Secondary Cancer Following Targeted Alpha Therapy with Astatine-211 Intraperitoneal Radioimmunotherapy.” Journal of Nuclear Medicine, vol. 63, no. 10, Oct. 2022, pp. 1–41. EBSCOhost, https://doi.org/10.2967/jnumed.121.263349.

APA

Leidermark, E., Hallqvist, A., Jacobsson, L., Karlsson, P., Holmberg, E., Bäck, T., Johansson, M., Lindegren, S., Palm, S., & Albertsson, P. (2022). Estimating the risk for secondary cancer following targeted alpha therapy with astatine-211 intraperitoneal radioimmunotherapy. Journal of Nuclear Medicine, 63(10), 1–41. https://doi.org/10.2967/jnumed.121.263349

Chicago

Leidermark, Erik, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm, and Per Albertsson. 2022. “Estimating the Risk for Secondary Cancer Following Targeted Alpha Therapy with Astatine-211 Intraperitoneal Radioimmunotherapy.” Journal of Nuclear Medicine 63 (10): 1–41. doi:10.2967/jnumed.121.263349.